Vical to Present HSV-2 Phase 1/2 Data at June ASM Microbe/ICAAC 2016 Conference
June 13 2016 - 6:30AM
Vical Incorporated (Nasdaq:VICL) announced today that the company
will present clinical data on its completed HSV-2 Phase 1/2 trial
at the American Society of Microbiology (ASM) Microbe/ICAAC 2016
conference (Boston, June 16 - 20).
Dr. Mammen P. “Anza” Mammen, M.D. Vical’s Vice
President, Clinical Vaccines, will present in the conference’s
clinical virology session on June 20, 2016 at approximately 10:30
am. Trial results, including safety and efficacy endpoints, will be
presented in the oral late-breaker presentation. The slides
presented by Dr. Mammen will be available on Vical’s website after
the presentation.
About VicalVical develops
biopharmaceutical products for the prevention and treatment of
chronic or life-threatening infectious diseases, based on its
patented DNA delivery technologies and other therapeutic
approaches. Additional information on Vical is available at
www.vical.com.
Contact:
Andrew Hopkins
(858) 646-1127
Website: www.vical.com
Vical (NASDAQ:VICL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vical (NASDAQ:VICL)
Historical Stock Chart
From Sep 2023 to Sep 2024